Metabolic syndrome in people with schizophrenia: a review.
about
Schizophrenia: a multisystem disease?Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementAn overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologistsIs the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsTheranostic Biomarkers for SchizophreniaCare provided by general practitioners to patients with psychotic disorders: a cohort studyUnderstanding the problems developing a healthy living programme in patients with serious mental illness: a qualitative study.Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data.Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?Almost all antipsychotics result in weight gain: a meta-analysis.Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Enhanced physical health screening for people with severe mental illness in Hong Kong: results from a one-year prospective case series studyDietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).Cardiovascular risk factors and 30-year cardiovascular risk in homeless adults with mental illnessProtocol for CHANGE: a randomized clinical trial assessing lifestyle coaching plus care coordination versus care coordination alone versus treatment as usual to reduce risks of cardiovascular disease in adults with schizophrenia and abdominal obesitWeight Gain and Its Correlates Among Forensic InpatientsReducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study.Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorderUse of an electronic metabolic monitoring form in a mental health service - a retrospective file audit.The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional studySafety evaluation of saffron stigma (Crocus sativus L.) aqueous extract and crocin in patients with schizophreniaHigh Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide SurveyCardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.Perceived needs and health-related quality of life in people with schizophrenia and metabolic syndrome: a "real-world" study.Clozapine modifies the differentiation program of human adipocytes inducing browning.Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.Retrospective study of Japanese patients with schizophrenia treated with aripiprazole.Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients.Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.Genetic underpinnings of left superior temporal gyrus thickness in patients with schizophreniaRisk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluationA comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practiceTranslation of the diabetes prevention program into a community mental health organization for individuals with severe mental illness: a case study.The Northampton Physical Health and Wellbeing Project: the views of patients with severe mental illness about their physical health checkAntipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome
P2860
Q24633845-A9A99C7E-1B30-4E06-8B68-8C16B3E057A1Q26783003-102B906C-6509-4F5D-9674-11F37A447FFDQ26859927-6D94087F-0E87-4445-AF88-7FABA8959251Q27027832-15A68319-E7F8-4E0F-805A-F4B8759BE00FQ33624412-DDE580E3-8173-41F4-A0A2-5C5420501468Q33756112-D67DF7EB-D4D0-4137-8262-12FA03BCE297Q33902514-68C7DBD7-8F49-459F-8D21-77842C4921E5Q34086096-1160B85F-9CBF-4B62-AF03-F55C33E35E21Q34183495-08F472B4-FCB8-4B28-90AF-624B0982D462Q34486175-173CBB50-1003-41E8-ACAA-9A08368B5775Q34623350-BAC9DCCE-19E5-4AE2-B66D-14449E6ABD5AQ34634393-663FF8BD-E356-4F83-8123-CBF1DFDCC9C5Q34661499-DE45AE28-8DCE-4CB1-B144-6A59B22AE5FAQ35016170-098C424D-CD1F-487E-AEEE-5362BF04A61FQ35088447-A6616134-8CA5-44CD-AE19-9BA8FB80FE5FQ35103964-035C5914-FA46-4497-9853-B4DD73913D82Q35116048-45C62D9E-4525-4331-ABEA-CA12EDFD5881Q35118808-0120E390-1523-44B1-B8A6-38DEBB89402CQ35700367-6D557D23-74DB-4B80-9092-A05BC36DCF4CQ35794607-74D5D0D4-EDF4-485D-84D6-DDF846AA94F1Q35906535-9BB9F829-BE08-4691-B714-7A3C454B6BBAQ35993230-298CC71E-38DA-4BBE-91EB-58C557A0328CQ35994346-EC3D9D5E-FE9E-40D0-89E1-3985FC5DFBB0Q36049333-91F50A74-0F58-46A1-A612-20DE6AE15CD9Q36140242-35E638AC-E7DA-4064-94E3-7CEFBBD8DE1CQ36195246-C9802994-C2C2-4DD4-96E9-57CBB0C78E71Q36198276-FD8002E1-EFE8-47DE-9872-CDFDC8E817E3Q36200184-050CEBAA-3D21-42E6-B7EE-8DDC03DCCCD2Q36206591-7F3DAB23-14FF-45DF-B0C4-22E52A412352Q36213557-C8FDE045-9E48-4C8D-825F-85F240293777Q36219618-A759AB90-F57B-48F4-B4E4-C53A3766BE69Q36303695-A8EEDDCB-832F-4BB7-99FD-B60859EFE957Q36621075-69E49740-8AF6-49AD-B485-873E16F997FFQ36698123-CB5A01E4-3742-43E9-B29B-AE725F5881F9Q36755212-314F5824-5FEE-4B26-B2F1-62166435C4FDQ36771558-D7933880-07CA-413B-A192-C2064A13D415Q36843480-566653FD-F435-475F-85AE-1619AE226206Q37030481-5060A884-D77E-4D58-A0E3-A302CEF4C8A8Q37041880-50EF1E86-E512-4C55-9A9D-14A6A5D0F045Q37043479-B6400FF8-71DB-4ADF-920D-D218A45901B1
P2860
Metabolic syndrome in people with schizophrenia: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolic syndrome in people with schizophrenia: a review.
@en
Metabolic syndrome in people with schizophrenia: a review.
@nl
type
label
Metabolic syndrome in people with schizophrenia: a review.
@en
Metabolic syndrome in people with schizophrenia: a review.
@nl
prefLabel
Metabolic syndrome in people with schizophrenia: a review.
@en
Metabolic syndrome in people with schizophrenia: a review.
@nl
P2093
P2860
P1433
P1476
Metabolic syndrome in people with schizophrenia: a review
@en
P2093
Davy Vancampfort
Marc DE Hert
Ruud VAN Winkel
Vincent Schreurs
P2860
P356
10.1002/J.2051-5545.2009.TB00199.X
P407
P577
2009-02-01T00:00:00Z